
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3025117/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. Cerebellum, 2022, 21, 632-646.	2.5	8
2	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	10.2	210
3	Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome. Metabolites, 2022, 12, 291.	2.9	14
4	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Annals of Neurology, 2021, 89, 610-616.	5.3	68
5	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. Human Brain Mapping, 2021, 42, 2399-2415.	3.6	10
6	Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study. Journal of Medical Internet Research, 2021, 23, e30394.	4.3	21
7	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Annals of Neurology, 2021, 90, 477-489.	5.3	16
8	Central nervous system atrophy predicts future dynamics of disability progression in a realâ€world multiple sclerosis cohort. European Journal of Neurology, 2021, 28, 4153-4166.	3.3	10
9	Fingolimod in children with Rett syndrome: the FINGORETT study. Orphanet Journal of Rare Diseases, 2021, 16, 19.	2.7	12
10	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. Journal of Neurology, 2020, 267, 192-202.	3.6	12
11	Levels of brainâ€derived neurotrophic factor in patients with multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 2251-2261.	3.7	23
12	Growth differentiation factor 15 is increased in stable MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
13	Longitudinal patterns of cortical thinning in multiple sclerosis. Human Brain Mapping, 2020, 41, 2198-2215.	3.6	26
14	Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. Journal of Neurology, 2020, 267, 1536-1546.	3.6	35
15	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
16	Preferential spinal cord volume loss in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 947-957.	3.0	44
17	Plasma proteome in multiple sclerosis disease progression. Annals of Clinical and Translational Neurology, 2019, 6, 1582-1594.	3.7	21
18	Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases. Human Brain Mapping, 2019, 40, 4091-4104.	3.6	22

#	Article	IF	CITATIONS
19	Cerebrospinal fluid from Alzheimer's disease patients promotes tau aggregation in transgenic mice. Acta Neuropathologica Communications, 2019, 7, 72.	5.2	16
20	Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2019, 76, 274.	9.0	56
21	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	3.0	19
22	Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum. ENeuro, 2018, 5, ENEURO.0419-17.2018.	1.9	95
23	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. European Neurology, 2018, 80, 207-214.	1.4	5
24	Spinal cord volume loss. Neurology, 2018, 91, e349-e358.	1.1	66
25	Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 14-20.	2.0	13
26	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 2018, 141, 2382-2391.	7.6	345
27	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	5.3	768
28	Multiple Sclerosis: Associations Between Physical Disability and Depression Are Not Mediated by Self-Reported Physical Activity. Perceptual and Motor Skills, 2017, 124, 974-991.	1.3	4
29	Clinical studies and antiâ€inflammatory mechanisms of treatments. Epilepsia, 2017, 58, 69-82.	5.1	34
30	Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study. International Journal of Molecular Sciences, 2016, 17, 489.	4.1	11
31	Efficacy and Safety of Fingolimod in an Unselected Patient Population. PLoS ONE, 2016, 11, e0146190.	2.5	18
32	Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). Journal of Neurology, 2016, 263, 1364-1374.	3.6	13
33	Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis. NeuroImage: Clinical, 2016, 12, 466-477.	2.7	78
34	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	110
35	Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations. NeuroImage, 2015, 108, 87-94.	4.2	6
36	Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 1909-1917.	3.6	18

#	Article	IF	CITATIONS
37	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 410-418.	1.9	111
38	Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 202-213.	3.0	30
39	Labelâ€fusionâ€segmentation and deformationâ€based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability. Human Brain Mapping, 2014, 35, 4193-4203.	3.6	34
40	Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis. Brain Topography, 2014, 27, 318-327.	1.8	15
41	MRI characteristics of periaqueductal lesions in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 542-551.	2.0	13
42	The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 356-364.	3.0	76
43	Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial. PLoS ONE, 2014, 9, e86663.	2.5	31
44	Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis. PLoS ONE, 2014, 9, e86916.	2.5	73
45	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 281-288.	3.0	20
46	Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. European Journal of Radiology, 2013, 82, e848-e852.	2.6	12
47	Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1290-1296.	3.0	103
48	Utility of neuropsychological testing for guiding treatment decisions in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 366-368.	3.0	2
49	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. Radiology, 2013, 269, 542-552.	7.3	52
50	Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1577-1584.	3.0	26
51	Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. Journal of Neurology, 2012, 259, 2401-2413.	3.6	37
52	Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. Journal of Neurology, 2012, 259, 2673-2680.	3.6	27
53	3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. Multiple Sclerosis Journal, 2012, 18, 1570-1576.	3.0	29
54	Multivariate pattern classification of gray matter pathology in multiple sclerosis. NeuroImage, 2012, 60, 400-408.	4.2	47

#	Article	IF	CITATIONS
55	Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1560-1569.	3.0	82
56	Longitudinal gray matter changes in multiple sclerosis—Differential scanner and overall diseaseâ€related effects. Human Brain Mapping, 2012, 33, 1225-1245.	3.6	40
57	Clinical EEG in cognitively impaired patients with Parkinson's Disease. Journal of the Neurological Sciences, 2011, 310, 75-78.	0.6	17
58	Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis—A longitudinal MRI study. Brain Research, 2010, 1325, 174-182.	2.2	31
59	Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsingâ€remitting multiple sclerosis. Human Brain Mapping, 2010, 31, 1542-1555.	3.6	42
60	Acute Vertigo with Double Vision – Brainstem Stroke or Stroke Mimic?. Cerebrovascular Diseases, 2010, 30, 626-627.	1.7	3
61	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419
62	Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis — A longitudinal voxel-based morphometry study. NeuroImage, 2009, 45, 60-67.	4.2	83
63	Intravenous levetiracetam: Treatment experience with the first 50 critically ill patients. Epilepsy and Behavior, 2008, 12, 477-480.	1.7	102
64	Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis. Brain, 2008, 131, 1776-1782.	7.6	18
65	Beta Activity in Status Epilepticus. Epilepsia, 2006, 47, 207-210.	5.1	30